| Literature DB >> 28426973 |
Kyle K L Phua1, Yi Liu2, Shun Hui Sim3.
Abstract
Nucleic acid induced immunogenicity remains a significant impediment in biomedical therapeutics because the innate immune system is a complex network overlaid with functional redundancies. Herein we report that non-structural protein 1 (NS1), an immune evasion protein derived from influenza A virus, when co-delivered in mRNA format is a potent mRNA transfection enhancer without toxicity. Transfection enhancement is mediated by NS1's effector domain through inhibition of IRF3 and PKR, activators of early anti-viral responses as well as CPSF30, a non immunostimulating protein. Importantly, host gene inhibition mediated via CPSF30 inhibition is a highly effective immune evasion mechanism because it blocks de novo gene expression non-specifically and inhibits global anti-viral responses during mRNA transfection. We show that only NS1 with CPSF30 inhibition property can enhance modified mRNA transfections. Furthermore, transfection efficiency of unmodified mRNA, if co-delivered with NS1-TX91 mRNA, can exceed that of modified mRNA in HepG2, RAW 264.7 and HeLa cells. The novel impact of NS1-TX91 lays the foundation of a virus inspired immune evasion genes co-delivery approach that can address problems arising from RNA immunogenicity for non-vaccine mRNA therapeutics in an affordable and scalable way. It is also transferable to applications that benefits from active inhibition of material-induced immunogenicity.Entities:
Keywords: Anti-viral response; Immune evasion genes; Interferon; Modified mRNA; mRNA delivery; mRNA therapeutics; mRNA transfection
Mesh:
Substances:
Year: 2017 PMID: 28426973 DOI: 10.1016/j.biomaterials.2017.04.009
Source DB: PubMed Journal: Biomaterials ISSN: 0142-9612 Impact factor: 12.479